DZP is advising the oldest of the Polish pharmaceutical companies, TZF "Polfa" S.A., in a project to build an Oncology Medicines Development and Manufacturing Centre. The facility will be the largest plant manufacturing oncology medicines in Poland and in our part of Europe. DZP's lawyers have advised in particular on the conclusion and implementation of works contracts with Budimex S.A. and Karmar S.A.
In this investment, which is worth up to PLN 500 million, two production lines will be constructed in a building with an area of 12,000 m2. The lines will be designed, constructed and tested by IMA, a global leader in the design and manufacture of automatic machines for the manufacture and packaging of, inter alia, pharmaceuticals. The company is planning to obtain a use permit for the new facility by the end of Q1 2024, with the opening of the first Oncology Medicines Development and Manufacturing Centre in Poland and in our region planned for the end of 2024/beginning of 2025.
The new pharmaceuticals facility is to focus on the manufacture of anticancer medicines for the treatment of, inter alia, breast cancer, acute leukaemia and multiple myeloma. The facility will also manufacture highly active medicines used in the treatment of fungal diseases, in rheumatology and in anaesthesiology, as well as injectable antibiotics.
DZP's lawyers have supported TZF Polfa at every stage of the project, starting with the selection of contractors and conclusion of a works contract in Phase I of the project with Budimex S.A. and a works contract in Phase II implemented by Karmar S.A. We are currently advising the company during contract implementation.
The project is being handled by an interdisciplinary team led by Tomasz Darowski, Partner in the Infrastructure & Energy Practice, comprising Kamil Pociecha from the Construction Team, Katarzyna Kuźma, Tomasz Michalczyk and Wojciech Hartung from the Public Procurement Team, Anna Glapa from the State Aid Team, and lawyers from the Real Estate Practice, co-managed by Lech Żyżylewski.
TZF Polfa S.A. is the oldest pharmaceutical plant in Poland and one of the oldest in Europe, and is celebrating its 200th anniversary this year. It was TZF Polfa S.A. that first began manufacturing penicillin in the country, marking the beginning of the manufacturing of Polish antibiotics. Today, with 30 production lines and a portfolio of 50 medicinal products and medical devices, the company is investing significantly in development and employs nearly 900 people.